TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06787846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group TP
Description: Serum : Application full face, twice daily, in the morning and at bedtime for 4 months and application Tinted sunscreen SPF 50+, twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Group HQ: Hydroquinone 4%
Description: Cream : Application all over the face once a day (at bedtime) and Tinted sunscreen SPF 50+, twice a day
Study: NCT06787729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth
Description: The experimental design is composed of three phases: baseline, intervention, and retention. During the first two weeks (baseline), subjects will wear sensors, but no additional features (e.g., feedback, goal-setting, and weekly Zoom calls with clinicians) will be provided. For the next four weeks (intervention), subjects will wear sensors and have access to all intervention features, including weekly Zoom calls and goal-setting with clinicians. They will be encouraged to use the more impaired arm as much as possible. In the final two weeks (retention), the mobile intervention and clinician interactions will be removed, while subjects continue to wear sensors to examine the effects of withdrawing feedback.
Study: NCT06782880

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: To assess if heterologous FMT is more effective than autologous FMT in reducing the rate of major infection episodes within 6-months after OLT.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: To assess if heterologous FMT is more effective than autologous FMT in reducing the rate of major infection episodes within 6-months after OLT.
Study: NCT06785727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin)
Description: The intervention group receives statin treatment following the current Herseninfarct en Hersenbloeding guideline. The intensity and target value of statin treatment are determined according to this national guideline. Which statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin) will be selected and what dose will be prescribed is left to the discretion of the treating neurologist. The statins are registered in the Netherlands and use will be according to the licenses of the products. They will be collected at the local pharmacy by the patient (following practice as usual).
Study: NCT06786520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: CAB LA injection will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB ULA
Description: CAB ULA injection will be administered
Study: NCT06784830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effects on Image Quality and Patient Satisfaction
Description: Effect of nursing intervention on image quality and patient satisfaction during PET/CT imaging in Alzheimer's patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety degree of patients after nursing
Description: Self Rating Anxiety will be used Scale (SAS) to assess the degree of anxiety after care
Study: NCT05886036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive FDG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Receive FDG

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05194683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Letter Writing
Description: The intervention consists of two interviews and a between-session writing task. In the first session, couples will be interviewed regarding their relationship story and preferences. Between the two sessions, each couple member will write a letter from their relationship point of view. In the second interview, the task is reviewed and paths for relationship improvement are outlined.
Study: NCT04582383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Dispensation of spironolactone according to the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Hyclate
Description: Dispensation of doxycycline hyclate according to the arm description.
Study: NCT05331105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: IIa: HL-085 capsule 9mg administered orally twice daily in a continuous 21-day treatment cycle. If required, dosing schedule can be adjusted to 12mg BID, 6mg BID, or other dosage regimens.~IIb: HL-085 at the recommended dose or dosage regimen.
Study: NCT05886036

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study: NCT06784336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron chelation
Description: Patients will receive Iron chelation with deferasirox (Jadenu 7 mg/kg/day preferred versus Exjade 10 mg/kg/day) beginning on day -14 and continuing through day +100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potato Resistant Starch
Description: Patients will receive PRS beginning on day -6 and continuing through day +100. Patients will take 20g packet twice daily
Study: NCT06785649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender herbal tea
Description: The participant will be allocated 14 pieces of lavender tea bags consisting of 2 grams and originating from Turkey. During 14 days, the participant will be advised to use 2 g of lavender herb brewed in 300 mL hot water for 10-15 minutes in the morning and evening. Participants will be able to use 1 lavender tea bag twice a day.
Study: NCT04473534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web based cognitive-behavioral therapy
Description: one web session of psycho-education about sleep

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web based cognitive-behavioral therapy
Description: one web session of psycho-education about sleep
Study: NCT06786299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RD-IIT-001
Description: Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD84-CART
Description: Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy
Study: NCT06785142

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Functional Shot
Description: 60ml functional energy shot contained a proprietary blend of L-theanine, chamomile, lemon balm, ginseng and vitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Functional Shot
Description: 60ml functional energy shot contained a proprietary blend of L-theanine, chamomile, lemon balm, ginseng and vitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Functional Shot
Description: 60ml functional energy shot contained a proprietary blend of L-theanine, chamomile, lemon balm, ginseng and vitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Functional Shot
Description: 60ml functional energy shot contained a proprietary blend of L-theanine, chamomile, lemon balm, ginseng and vitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo Shot
Description: Placebo 60 ml Shot, matched in volume, taste and colour and but did not contain any active ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo Shot
Description: Placebo 60 ml Shot, matched in volume, taste and colour and but did not contain any active ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo Shot
Description: Placebo 60 ml Shot, matched in volume, taste and colour and but did not contain any active ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo Shot
Description: Placebo 60 ml Shot, matched in volume, taste and colour and but did not contain any active ingredients
Study: NCT06783075

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MILK
Description: Drink containing amino acids in the composition of milk protein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WHEAT
Description: Drink containing amino acids in the composition of wheat protein
Study: NCT06783400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SASA! Together
Description: SASA! Together is a community mobilisation approach that engages communities to create positive and sustainable changes around norms and behaviors that perpetuate violence against women. Some new features in this revision of SASA! include a distinct focus on IPV, including sexual decision-making; three strategies aligned to the socio-ecological model that reach across the whole community (individuals, groups, and institutions); and more support to get organisations and communities started and to sustain change.~The evidence- and theory-based SASA! approach is grounded in: (1) benefits-based activism, (2) a gender-power analysis, (3) four phases of change (start, awareness, support, action) according to the stages of behaviour change, (4) holistic community engagement, (5) local activism, (6) community leadership, and (7) institutional strengthening.
Study: NCT06782659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP-001
Description: Oral liquid suspension of sildenafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP-001
Description: Oral liquid suspension of sildenafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagra
Description: Sildenafil film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagra
Description: Sildenafil film-coated tablet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASP-001
Description: Bottle/pump containing ASP-001 suspension

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASP-001
Description: Bottle/pump containing ASP-001 suspension
Study: NCT06552403

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A modified 5:2 intermittent fasting diet
Description: The modified 5:2 IF diet involves 2 nonconsecutive fasting days (25%-30% of the total required daily energy intake based on ideal body weight) and 5 days of habitual intake (limited total energy intake according to ideal body weight) per week, as well as a 4-week run-in period and a minimum of 6,000 steps of physical activity per day.
Study: NCT06787859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Showing a nature view curtain to type 2 diabetic patients during insulin injection
Description: a nature view curtain
Study: NCT06782932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2373
Description: 1. Up to 3 doses (1 mg/kg, 3 mg/kg, and 10 mg/kg) will be tested in Phase I to determine the dose to be used in Phase II. AGEN2373 will be administered as a 60 minute IV infusion (-5/+15 min) on Day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 1 mg/kg, 3 mg/kg, and 10 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: 1. 450 mg will be administered as a 30 minute IV Infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 450 mg IV
Study: NCT05305456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanreqing capsule
Description: 3 capsules per time, 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tanreqing capsule simulator
Description: 3 capsules per time, 3 times a day
Study: NCT05294809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PsyPills
Description: Prescribing personalized rational thinking strategies to change levels of dysfunctional emotionality.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-Contingent Attention Training, OCAT
Description: Facilitating the disengagement from negative content and engagement of positive one of personally relevant information by providing instruction and feedback on performance.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: shamOCAT
Description: The active control group, which consists of the fake version of the OCAT intervention, by offering the same attentional training, without training and feedback on performance.
Study: NCT06782932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1. 200 mg/m2 will be administered as a 30 minute IV infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 200 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX
Description: 1. Vaccine (5 × 108 cells) will be administered on Day 2 of each cycle for a total of 6 cycles of treatment. Six intradermal injections will be given in the upper thighs and non-dominant arms. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: GVAX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN2373 (RP2D)
Description: 1. Drug: Up to 3 doses (1 mg/kg, 3 mg/kg, and 10 mg/kg) will be administered as a 60 minute IV. Infusion (-5/+15 min) on Day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 1 mg/kg, 3 mg/kg, and 10 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: 1. 450 mg will be administered as a 30 minute IV. Infusion (-5/+15 min) on day 1 of each cycle for a total of 6 cycles of treatment. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. Drug: 450 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mKRASvax
Description: 1. mKRASvax will be administered on Day 1 of each cycle and on Day 8 of Cycle 1 only. mKRASvax is given as 5 subcutaneous injections administered in the upper thighs and arms. Cycle 1 (14 days) is prior to surgical resection, Cycle 2 (14 days) is after surgery and prior to standard of care chemotherapy, and Cycles 3-6 (21 days) are given after completion of chemotherapy.~2. 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC
Study: NCT06787937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VLNC messages
Description: Participants will be exposed to messaging about VLNCs and reduced nicotine policy through multiple formats, including inserts placed in cigarette packs, printed advertisements, and video materials presented during their weekly visits.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control message
Description: Participants will be exposed to control messages, such as advertisements for bottled water, during their weekly visits.
Study: NCT06784115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reminder App
Description: The purpose of the app is to remind patients irradiated for prostate cancer in an intuitive, unobtrusive and supportive way to drink 300 ml of water 45 minutes prior to each radiation session.
Study: NCT06782997

Intervention type: DEVICE
Intervention: Electroretinogram
Description: Electroretinogram (RETevalTM devices, LKC Technologies) performed and interpreted by an advanced practice nurse compared to the gold standard (retinography) interpreted by an ophthalmologist
Study: NCT06786351

Intervention type: PROCEDURE
Intervention: Right atrial balloon occlusion
Description: Thoracic endovascular aortic repair with right atrial balloon occlusion for reduction or elimination of aortic impulse and stent graft deployment in landing zones 0-3

Intervention type: PROCEDURE
Intervention: Non right atrial balloon occlusion
Description: Thoracic endovascular aortic repair not using right atrial balloon occlusion for reduction or elimination of aortic impulse and stent graft deployment in landing zones 0-3
Study: NCT06785051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-based physiotherapy
Description: jaw, neck, shoulder ROM exercises, and scapular-focused exercises guided by AI technology, 30 minutes of intervention, once a week, and a total of 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: jaw, neck, shoulder ROM exercises, and scapular-focused exercises, 30 minutes of intervention, once a week, and a total of 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Scar management
Description: scar massage and jaw-mobilizing exercises combined with devices or depressors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scar management
Description: scar massage and jaw-mobilizing exercises combined with devices or depressors
Study: NCT06783621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Intramuscular Injections

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM
Description: Injections

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting Elite System
Description: CoolSculpting Elite Applicator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinMedica Products
Description: Skincare Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KYBELLA
Description: Injections
Study: NCT06782555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evofosfamide
Description: Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evofosfamide
Description: Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evofosfamide
Description: Evofosfamide administered on Days 1 and 8 of Cycles 1, 2, and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalifrelimab
Description: Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalifrelimab
Description: Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalifrelimab
Description: Zalifrelimab administered on Day 8 of Cycles 1, 3, and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab administered every 2 weeks beginning on Day 8 of Cycle 1.
Study: NCT06783855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suspension uretheroileal technique
Description: The suspension technique is reported as the puboprostatic ligaments that attach the prostate to the symphysis pubis. After the ligating the complex, including both the dorsal vein complex and the puboprostatic ligaments, this complex was sharply divided anteriorly from the prostate with a safe distance (1-2 mm), and the urethra is defined and divided. After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions through the full thickness of the urethra

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional radical cystectomy and ileal neobladder
Description: After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions through the full thickness of the urethra, including the mucosa and muscularis of the neobladder neck, ensuring mucosa-to-mucosa anastomosis
Study: NCT06786650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenoxicam Injectable Product
Description: Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ibuprofen
Description: Analgesic efficacy of the two active agents analysed in our study in acute migraine attack has not been compared before.
Study: NCT06787014

Intervention type: OTHER
Intervention: Histopathological review
Description: Histopathological review
Study: NCT06787781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid
Description: ALA was administrated in capsules at a xed oral daily dose of 600 mg for the entire duration of the study in addition to the atypical antipsychotic therapy.
Study: NCT06783881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kylo-12
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.